Develops oral tablet vaccine candidates for infectious diseases and HPV-related disease, working with government agencies and pharmaceutical partners.
10-K for FY2025, filed Mar 13, 2026We are a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on our…View ↗
We are developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus (a widespread cause of…View ↗
In January 2024, we were awarded the 2024 ASPR-BARDA Contract by HHS BARDA, with a base and all options value of $9.3 million. Under the…View ↗
On November 4, 2025, the Company entered into an Exclusive License and Collaboration Agreement (“2025 License and Collaboration Agreement”)…View ↗
Most revenue comes from government contracts: BARDA pays for COVID-19 trial work through reimbursement of eligible costs as they are incurred and fixed-price milestones when completed. Dynavax paid an upfront fee for a vaccine license, with further development, milestone and possible sales-royalty payments.
S-1, filed May 8, 2026 10-K for FY2025, filed Mar 13, 2026The Company accounts for the 2024 ATI-RRPV Contract under ASC 958-605 and recognizes revenue as the firm fixed-price milestone is earned…View ↗
On November 4, 2025, the Company entered into an Exclusive License and Collaboration Agreement (“2025 License and Collaboration Agreement”)…View ↗
The agreement also includes a development collaboration component under which the Company is responsible for completing its ongoing Phase…View ↗
$237.3M
10-K for FY2025, filed Mar 13, 2026
$237.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Non Cash Royalty Revenue
Licensed
|
0.8%
FY2022: 100%
|
Non Cash Royalty Revenue, FY2025
$1.9M Sources
|
Licensed |
|
Government Contract
|
95% |
Government Contract, FY2025
$224.5M Sources
|
|
|
License
Licensed
|
3.7% |
License, FY2025
$8.7M Sources
|
Licensed |
|
Collaboration Revenue
Recurring
|
0.9% |
Collaboration Revenue, FY2025
$2.1M Sources
|
Recurring |
Vaxart contracts with Advanced Technology International for BARDA-funded vaccine-trial work; Dynavax holds an exclusive worldwide license to the COVID-19 candidate, and Daiichi Sankyo markets Inavir in Japan.
10-K for FY2025, filed Mar 13, 2026In June 2024, the Company entered into an agreement (as modified or amended from time to time, the “2024 ATI-RRPV Contract”) with Advanced…View ↗
On November 4, 2025, the Company entered into an Exclusive License and Collaboration Agreement (“2025 License and Collaboration Agreement”)…View ↗
The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen…View ↗
Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 3 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$17.7MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Jun 26, 2026
Pursuant to the Modification, the total amount of funding available for payment under the Project Agreement is approximately $345 million…View ↗
Growing. Revenue grew 266.0x in 4 years, from $892K in FY2021 to $237.3M in FY2025, about 304% a year.
Competes with Moderna, Anhui Zhifei Longcom Biopharmaceutical, Chongqing Zhifei Biological Products, National Vaccine and Serum Institute of China, Cocrystal Pharma, Pfizer-BioNTech, Novavax, AstraZeneca, CSL, Emergent BioSolutions, F. Hoffmann-La Roche, GSK, Instituto Butantan, Merck &, Pfizer, Sanofi, Sinovac Biotech, Centivax, Inovio Pharmaceuticals, and Genexine
10-K for FY2025, filed Mar 13, 2026As of January 2026, there are no vaccines approved by the FDA or other global regulatory agencies for the prevention of norovirus. We are…View ↗
Loading...